bimekizumab

Home
Ligands
bimekizumab

GtoPdb Ligand ID: 9411

Synonyms: bimekizumab-bkzx | Bimzelx® | CA028_0496 | CDP4940 | gL7gH9 | UCB-4940 | UCB4940 | Zu-G1

bimekizumab is an approved drug (EMA (2021), FDA (2023))

Comment: Bimekizumab (UCB4940) is a rat-derived humanized monoclonal antibody that simultaneously targets IL-17A and IL-7F (dual antagonist), with potential for controlling autoimmune conditions mediated by these proinflammatory cytokines. Safety, pharmacokinetics and clinical efficacy of bimekizumab in mild psoriasis were reported in [2]. Claimed in patent WO2008047134 as CA028_0496 [1].

No information available.

No information available.

Summary of Clinical Use
First-in-human clinical trial was NCT02529956, which reported clinically meaningful efficacy [2] and led to further development of bimekizumab in IL-17A- and IL-17 F-mediated diseases, including rheumatoid arthritis, psoriatic arthritis, chronic plaque psoriasis and ankylosing ppondylitis. The EMA approved bimekizumab as a treatment for plaque psoriasis in August 2021. FDA approval for this indication followed in 2023. FDA authorisation was expanded in September 2024, to include treatment of active psoriatic arthritis, active non-radiographic axial spondyloarthritis and active ankylosing spondylitis, and again in November that year include hidradenitis suppurativa.

Summary of Clinical Use

First-in-human clinical trial was NCT02529956, which reported clinically meaningful efficacy [2] and led to further development of bimekizumab in IL-17A- and IL-17 F-mediated diseases, including rheumatoid arthritis, psoriatic arthritis, chronic plaque psoriasis and ankylosing ppondylitis.
The EMA approved bimekizumab as a treatment for plaque psoriasis in August 2021. FDA approval for this indication followed in 2023. FDA authorisation was expanded in September 2024, to include treatment of active psoriatic arthritis, active non-radiographic axial spondyloarthritis and active ankylosing spondylitis, and again in November that year include hidradenitis suppurativa.

Mechanism Of Action and Pharmacodynamic Effects
Antibody binds to IL-17A, IL-17F and the IL-17A/F heterodimer, neutralising their biological activity [1]. Dual antagonists of IL-17A and IL-17F may be more effective than a sole antagonist in treating IL-17 mediated diseases.

Mechanism Of Action and Pharmacodynamic Effects

Antibody binds to IL-17A, IL-17F and the IL-17A/F heterodimer, neutralising their biological activity [1]. Dual antagonists of IL-17A and IL-17F may be more effective than a sole antagonist in treating IL-17 mediated diseases.